company background image
AB

AB Science ENXTPA:AB Stock Report

Last Price

€9.30

Market Cap

€439.5m

7D

2.1%

1Y

-37.9%

Updated

24 May, 2022

Data

Company Financials
AB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

AB Stock Overview

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines.

AB Science Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for AB Science
Historical stock prices
Current Share Price€9.30
52 Week High€16.68
52 Week Low€6.95
Beta0.88
1 Month Change-11.51%
3 Month Change-6.53%
1 Year Change-37.88%
3 Year Change133.96%
5 Year Change-5.10%
Change since IPO-26.66%

Recent News & Updates

Shareholder Returns

ABFR PharmaceuticalsFR Market
7D2.1%3.5%-1.5%
1Y-37.9%17.8%-18.8%

Return vs Industry: AB underperformed the French Pharmaceuticals industry which returned 17.8% over the past year.

Return vs Market: AB underperformed the French Market which returned -18.8% over the past year.

Price Volatility

Is AB's price volatile compared to industry and market?
AB volatility
AB Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement6.0%
10% most volatile stocks in FR Market10.2%
10% least volatile stocks in FR Market3.5%

Stable Share Price: AB is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200198Alain Moussyhttps://www.ab-science.com

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19.

AB Science Fundamentals Summary

How do AB Science's earnings and revenue compare to its market cap?
AB fundamental statistics
Market Cap€439.54m
Earnings (TTM)-€14.46m
Revenue (TTM)€1.61m

271.2x

P/S Ratio

-30.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AB income statement (TTM)
Revenue€1.61m
Cost of Revenue€111.00k
Gross Profit€1.50m
Other Expenses€15.96m
Earnings-€14.46m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 30, 2022

Earnings per share (EPS)-0.31
Gross Margin93.09%
Net Profit Margin-900.00%
Debt/Equity Ratio-58.9%

How did AB perform over the long term?

See historical performance and comparison

Valuation

Is AB Science undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether AB Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AB Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is AB Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AB Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has AB Science performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AB is currently unprofitable.

Growing Profit Margin: AB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AB is unprofitable, but has reduced losses over the past 5 years at a rate of 15.7% per year.

Accelerating Growth: Unable to compare AB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).


Return on Equity

High ROE: AB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is AB Science's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AB has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AB is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is AB Science current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average board tenure


CEO

Alain Moussy

20.83yrs

Tenure

€622,000

Compensation

Mr. Alain Moussy, MBA is a Co-Founder of AB Science S.A. and has been its Chief Executive Officer since July 2001 and Managing Director. Mr. Moussy serves as Chairman since July 11, 2001 and serves as its...


CEO Compensation Analysis

Compensation vs Market: Alain's total compensation ($USD667.38K) is above average for companies of similar size in the French market ($USD462.48K).

Compensation vs Earnings: Alain's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: AB's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AB Science S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: AB Science S.A.
  • Ticker: AB
  • Exchange: ENXTPA
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €439.542m
  • Shares outstanding: 46.86m
  • Website: https://www.ab-science.com

Number of Employees


Location

  • AB Science S.A.
  • 3, Avenue George V
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.